View in EDS

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Authors: Grosicki S; Medical University of Silesia, Katowice, Poland. Electronic address: sgrosicki@wp.pl., Simonova M; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine., Spicka I; Charles University and General Hospital, Prague, Czech Republic., Pour L; Clinic of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Kriachok I; National Cancer Institute Ukraine, Kiev, Ukraine., Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine., Auner HW; Imperial College London, London, UK., Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France., Doronin V; City Clinical Hospital No. 40, Moscow, Russia., Usenko G; City Clinical Hospital 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine., Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada., Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Benjamin R; Kings College NHS Foundation Trust, Kings College London, London, UK., Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India., Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK., Gironella M; Vall d'Hebron University Hospital, Barcelona, Spain., Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Kraków, Poland., Robak P; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland., Galli M; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy., Wallington-Beddoe C; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia., Radinoff A; University Hospital 'St Ivan Rilski' EAD, Sofia, Bulgaria., Salogub G; Chemotherapy of Oncology Diseases-Bone Marrow Transplantation Department 1, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia., Stevens DA; Norton Cancer Institute, St Matthews Campus, Louisville, KY, USA., Basu S; New Cross Hospital, Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, UK., Liberati AM; Oncohematology Hospital S Maria Terni, University of Perugia, Terni, Italy., Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia., Goranova-Marinova VS; University Hospital 'Sv Georgi' EAD, Clinic of Clinical Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria., Bila J; Clinic for Hematology, Clinical Centre of Serbia, Belgrade, Serbia., Katodritou E; Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece., Oliynyk H; Department of Hematology, Vinnytsia M I Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine., Korenkova S; Bone Marrow Transplantation Department, Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine., Kumar J; Tata Medical Center, Kolkata, India., Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Moreau P; University Hospital, Hotel-Dieu, Nantes, France., Levy M; Baylor University Medical Center, Dallas, TX, USA., White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada., Gatt ME; Hadassah Hebrew University Medical Center, Jerusalem, Israel., Facon T; CHU Lille Service des Maladies du Sang F-59000, Lille, France., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Cavo M; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy., Reece D; University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada., Anderson LD Jr; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Saint-Martin JR; Karyopharm Therapeutics, Newton, MA, USA., Jeha J; Karyopharm Therapeutics, Newton, MA, USA., Joshi AA; Karyopharm Therapeutics, Newton, MA, USA., Chai Y; Karyopharm Therapeutics, Newton, MA, USA., Li L; Karyopharm Therapeutics, Newton, MA, USA., Peddagali V; Karyopharm Therapeutics, Newton, MA, USA., Arazy M; Karyopharm Therapeutics, Newton, MA, USA., Shah J; Karyopharm Therapeutics, Newton, MA, USA., Shacham S; Karyopharm Therapeutics, Newton, MA, USA., Kauffman MG; Karyopharm Therapeutics, Newton, MA, USA., Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA., Delimpasi S; General Hospital Evangelismos, Athens, Greece.
Source: Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1563-1573.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33189178
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Grosicki+S%22">Grosicki S</searchLink>; Medical University of Silesia, Katowice, Poland. Electronic address: sgrosicki@wp.pl.<br /><searchLink fieldCode="AU" term="%22Simonova+M%22">Simonova M</searchLink>; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; Clinic of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Kriachok+I%22">Kriachok I</searchLink>; National Cancer Institute Ukraine, Kiev, Ukraine.<br /><searchLink fieldCode="AU" term="%22Gavriatopoulou+M%22">Gavriatopoulou M</searchLink>; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Pylypenko+H%22">Pylypenko H</searchLink>; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.<br /><searchLink fieldCode="AU" term="%22Auner+HW%22">Auner HW</searchLink>; Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Doronin+V%22">Doronin V</searchLink>; City Clinical Hospital No. 40, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Usenko+G%22">Usenko G</searchLink>; City Clinical Hospital 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine.<br /><searchLink fieldCode="AU" term="%22Bahlis+NJ%22">Bahlis NJ</searchLink>; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Hajek+R%22">Hajek R</searchLink>; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Benjamin+R%22">Benjamin R</searchLink>; Kings College NHS Foundation Trust, Kings College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Dolai+TK%22">Dolai TK</searchLink>; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.<br /><searchLink fieldCode="AU" term="%22Sinha+DK%22">Sinha DK</searchLink>; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.<br /><searchLink fieldCode="AU" term="%22Venner+CP%22">Venner CP</searchLink>; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Garg+M%22">Garg M</searchLink>; University Hospitals of Leicester NHS Trust, Leicester, UK.<br /><searchLink fieldCode="AU" term="%22Gironella+M%22">Gironella M</searchLink>; Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Jurczyszyn+A%22">Jurczyszyn A</searchLink>; Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.<br /><searchLink fieldCode="AU" term="%22Robak+P%22">Robak P</searchLink>; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.<br /><searchLink fieldCode="AU" term="%22Galli+M%22">Galli M</searchLink>; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.<br /><searchLink fieldCode="AU" term="%22Wallington-Beddoe+C%22">Wallington-Beddoe C</searchLink>; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.<br /><searchLink fieldCode="AU" term="%22Radinoff+A%22">Radinoff A</searchLink>; University Hospital 'St Ivan Rilski' EAD, Sofia, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Salogub+G%22">Salogub G</searchLink>; Chemotherapy of Oncology Diseases-Bone Marrow Transplantation Department 1, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Stevens+DA%22">Stevens DA</searchLink>; Norton Cancer Institute, St Matthews Campus, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Basu+S%22">Basu S</searchLink>; New Cross Hospital, Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, UK.<br /><searchLink fieldCode="AU" term="%22Liberati+AM%22">Liberati AM</searchLink>; Oncohematology Hospital S Maria Terni, University of Perugia, Terni, Italy.<br /><searchLink fieldCode="AU" term="%22Quach+H%22">Quach H</searchLink>; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Goranova-Marinova+VS%22">Goranova-Marinova VS</searchLink>; University Hospital 'Sv Georgi' EAD, Clinic of Clinical Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Bila+J%22">Bila J</searchLink>; Clinic for Hematology, Clinical Centre of Serbia, Belgrade, Serbia.<br /><searchLink fieldCode="AU" term="%22Katodritou+E%22">Katodritou E</searchLink>; Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece.<br /><searchLink fieldCode="AU" term="%22Oliynyk+H%22">Oliynyk H</searchLink>; Department of Hematology, Vinnytsia M I Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine.<br /><searchLink fieldCode="AU" term="%22Korenkova+S%22">Korenkova S</searchLink>; Bone Marrow Transplantation Department, Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Kumar+J%22">Kumar J</searchLink>; Tata Medical Center, Kolkata, India.<br /><searchLink fieldCode="AU" term="%22Jagannath+S%22">Jagannath S</searchLink>; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; University Hospital, Hotel-Dieu, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Levy+M%22">Levy M</searchLink>; Baylor University Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22White+D%22">White D</searchLink>; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Gatt+ME%22">Gatt ME</searchLink>; Hadassah Hebrew University Medical Center, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Facon+T%22">Facon T</searchLink>; CHU Lille Service des Maladies du Sang F-59000, Lille, France.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hospital Universitario de Salamanca, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Cavo+M%22">Cavo M</searchLink>; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Reece+D%22">Reece D</searchLink>; University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Anderson+LD+Jr%22">Anderson LD Jr</searchLink>; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Saint-Martin+JR%22">Saint-Martin JR</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Jeha+J%22">Jeha J</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Joshi+AA%22">Joshi AA</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chai+Y%22">Chai Y</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Peddagali+V%22">Peddagali V</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Arazy+M%22">Arazy M</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shah+J%22">Shah J</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shacham+S%22">Shacham S</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kauffman+MG%22">Kauffman MG</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; General Hospital Evangelismos, Athens, Greece.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1563-1573.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33189178
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(20)32292-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1563
    Titles:
      – TitleFull: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Grosicki S
      – PersonEntity:
          Name:
            NameFull: Simonova M
      – PersonEntity:
          Name:
            NameFull: Spicka I
      – PersonEntity:
          Name:
            NameFull: Pour L
      – PersonEntity:
          Name:
            NameFull: Kriachok I
      – PersonEntity:
          Name:
            NameFull: Gavriatopoulou M
      – PersonEntity:
          Name:
            NameFull: Pylypenko H
      – PersonEntity:
          Name:
            NameFull: Auner HW
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Doronin V
      – PersonEntity:
          Name:
            NameFull: Usenko G
      – PersonEntity:
          Name:
            NameFull: Bahlis NJ
      – PersonEntity:
          Name:
            NameFull: Hajek R
      – PersonEntity:
          Name:
            NameFull: Benjamin R
      – PersonEntity:
          Name:
            NameFull: Dolai TK
      – PersonEntity:
          Name:
            NameFull: Sinha DK
      – PersonEntity:
          Name:
            NameFull: Venner CP
      – PersonEntity:
          Name:
            NameFull: Garg M
      – PersonEntity:
          Name:
            NameFull: Gironella M
      – PersonEntity:
          Name:
            NameFull: Jurczyszyn A
      – PersonEntity:
          Name:
            NameFull: Robak P
      – PersonEntity:
          Name:
            NameFull: Galli M
      – PersonEntity:
          Name:
            NameFull: Wallington-Beddoe C
      – PersonEntity:
          Name:
            NameFull: Radinoff A
      – PersonEntity:
          Name:
            NameFull: Salogub G
      – PersonEntity:
          Name:
            NameFull: Stevens DA
      – PersonEntity:
          Name:
            NameFull: Basu S
      – PersonEntity:
          Name:
            NameFull: Liberati AM
      – PersonEntity:
          Name:
            NameFull: Quach H
      – PersonEntity:
          Name:
            NameFull: Goranova-Marinova VS
      – PersonEntity:
          Name:
            NameFull: Bila J
      – PersonEntity:
          Name:
            NameFull: Katodritou E
      – PersonEntity:
          Name:
            NameFull: Oliynyk H
      – PersonEntity:
          Name:
            NameFull: Korenkova S
      – PersonEntity:
          Name:
            NameFull: Kumar J
      – PersonEntity:
          Name:
            NameFull: Jagannath S
      – PersonEntity:
          Name:
            NameFull: Moreau P
      – PersonEntity:
          Name:
            NameFull: Levy M
      – PersonEntity:
          Name:
            NameFull: White D
      – PersonEntity:
          Name:
            NameFull: Gatt ME
      – PersonEntity:
          Name:
            NameFull: Facon T
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Cavo M
      – PersonEntity:
          Name:
            NameFull: Reece D
      – PersonEntity:
          Name:
            NameFull: Anderson LD Jr
      – PersonEntity:
          Name:
            NameFull: Saint-Martin JR
      – PersonEntity:
          Name:
            NameFull: Jeha J
      – PersonEntity:
          Name:
            NameFull: Joshi AA
      – PersonEntity:
          Name:
            NameFull: Chai Y
      – PersonEntity:
          Name:
            NameFull: Li L
      – PersonEntity:
          Name:
            NameFull: Peddagali V
      – PersonEntity:
          Name:
            NameFull: Arazy M
      – PersonEntity:
          Name:
            NameFull: Shah J
      – PersonEntity:
          Name:
            NameFull: Shacham S
      – PersonEntity:
          Name:
            NameFull: Kauffman MG
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Delimpasi S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 11
              Text: 2020 Nov 14
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 396
            – Type: issue
              Value: 10262
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1